Novel baroreflex activation therapy in resistant hypertension results of a European multi-center feasibility study

Scheffers, I.J.; Kroon, A.A.; Schmidli, J.; Jordan, J.; Tordoir, J.J.; Mohaupt, M.G.; Luft, F.C.; Haller, H.; Menne, J.; Engeli, S.; Ceral, J.; Eckert, S.; Erglis, A.; Narkiewicz, K.; Philipp, T.; de Leeuw, P.W.

Novel baroreflex activation therapy in resistant hypertension results of a European multi-center feasibility study

Tools

Item Type:	Article
Title:	Novel baroreflex activation therapy in resistant hypertension results of a European multi-center feasibility study
Creators Name:	Scheffers, I.J., Kroon, A.A., Schmidli, J., Jordan, J., Tordoir, J.J., Mohaupt, M.G., Luft, F.C., Haller, H., Menne, J., Engeli, S., Ceral, J., Eckert, S., Erglis, A., Narkiewicz, K., Philipp, T. and de Leeuw, P.W.
Abstract:	OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An external programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
Keywords:	Baroreflex, Device, Feasibility, Hypertension, Treatment
Source:	Journal of the American College of Cardiology
ISSN:	0735-1097
Publisher:	Elsevier
Volume:	56
Number:	15
Page Range:	1254-1258
Date:	5 October 2010
Official Publication:	https://doi.org/10.1016/j.jacc.2010.03.089
PubMed:	View item in PubMed

Repository Staff Only: item control page